AstraZeneca’s Camizestrant Extends Survival in ESR1-Mutant Breast Cancer
CHICAGO, Illinois, USA, June 2, 2026 AstraZeneca has announced compelling new results from its pivotal Phase III SERENA-6 trial,...
Breast Cancer
Advertisement
Celcuity’s Gedatolisib Doubles Progression-Free Survival in Phase 3 Breast Cancer Trial
MINNEAPOLIS, Minnesota, USA , June 2, 2026 Celcuity has announced groundbreaking results from the Phase 3 VIKTORIA-1 clinical trial,...
FDA Accepts Genentech NDA for Giredestrant in Early Breast Cancer
SOUTH SAN FRANCISCO, Calif., June 1, 2026 Genentech announced that the U.S. Food and Drug Administration (FDA) has accepted...
Rallybio and Avenzo Merge to Advance Oncology Pipeline with $215M Financing
NEW HAVEN, Conn. & SAN DIEGO, Calif., June 2, 2026 Rallybio Corporation and Avenzo Therapeutics announced a definitive merger...
Avenzo Reports Promising Phase 1 Data for AVZO-021 in HR+ Breast Cancer
SAN DIEGO, Calif., June 1, 2026 Avenzo Therapeutics announced updated clinical results from the Phase 1 portion of its...
Advertisements
Protagonist to Showcase Phase 3 VERIFY and Long-Term Rusfertide Data at EHA 2026
NEWARK, Calif., June 1, 2026 Protagonist Therapeutics announced that four abstracts featuring rusfertide in polycythemia vera (PV) will be...
Natera Begins SIGNAL-ER 101 Trial for MRD-Guided Breast Cancer Therapy
AUSTIN, Texas — May 27, 2026 Natera, Inc. announced the enrollment of the first patients in the SIGNAL-ER 101...
Oncolytics’ Pelareorep Shows Strong KRAS-Targeted Immune Activation at ASCO 2026
SAN DIEGO, May 22, 2026 Oncolytics Biotech® announced new translational data from its GOBLET and AWARE-1 studies showing that...
Gilead’s Trodelvy Wins CHMP Support in 1L TNBC
FOSTER CITY, Calif., May 25, 2026 Gilead Sciences announced that the European Medicines Agency’s Committee for Medicinal Products for...
Veracyte Highlights Practice-Changing Cancer Test Data at ASCO 2026
SOUTH SAN FRANCISCO, California, 21 May 2026 Veracyte, Inc. announced that major Phase III clinical trial results involving its...
Advertisement
